Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CCXI's Cash to Debt is ranked higher than
84% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCXI' s Cash to Debt Range Over the Past 10 Years
Min: 6.43  Med: 720.51 Max: No Debt
Current: No Debt
Equity to Asset 0.42
CCXI's Equity to Asset is ranked lower than
77% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CCXI: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
CCXI' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.9 Max: 0.96
Current: 0.42
0.42
0.96
Interest Coverage No Debt
CCXI's Interest Coverage is ranked higher than
81% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CCXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CCXI' s Interest Coverage Range Over the Past 10 Years
Min: 206.51  Med: 5103.26 Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -1.30
M-Score: -3.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1748.66
CCXI's Operating margin (%) is ranked lower than
82% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. CCXI: -1748.66 )
Ranked among companies with meaningful Operating margin (%) only.
CCXI' s Operating margin (%) Range Over the Past 10 Years
Min: -1748.66  Med: -17.09 Max: 31.55
Current: -1748.66
-1748.66
31.55
Net-margin (%) -1733.35
CCXI's Net-margin (%) is ranked lower than
82% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. CCXI: -1733.35 )
Ranked among companies with meaningful Net-margin (%) only.
CCXI' s Net-margin (%) Range Over the Past 10 Years
Min: -1733.35  Med: -14.58 Max: 31.41
Current: -1733.35
-1733.35
31.41
ROE (%) -66.50
CCXI's ROE (%) is ranked lower than
70% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CCXI: -66.50 )
Ranked among companies with meaningful ROE (%) only.
CCXI' s ROE (%) Range Over the Past 10 Years
Min: -66.5  Med: -30.25 Max: 20.21
Current: -66.5
-66.5
20.21
ROA (%) -51.40
CCXI's ROA (%) is ranked lower than
69% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CCXI: -51.40 )
Ranked among companies with meaningful ROA (%) only.
CCXI' s ROA (%) Range Over the Past 10 Years
Min: -51.4  Med: -28.15 Max: 15.1
Current: -51.4
-51.4
15.1
ROC (Joel Greenblatt) (%) -5101.66
CCXI's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CCXI: -5101.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5101.66  Med: -2639.91 Max: 66.57
Current: -5101.66
-5101.66
66.57
Revenue Growth (3Y)(%) -100.00
CCXI's Revenue Growth (3Y)(%) is ranked lower than
99% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. CCXI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CCXI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: -50.7
Current: -100
EBITDA Growth (3Y)(%) -0.30
CCXI's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CCXI: -0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CCXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 56.3 Max: 121.1
Current: -0.3
0
121.1
EPS Growth (3Y)(%) -1.50
CCXI's EPS Growth (3Y)(%) is ranked higher than
52% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. CCXI: -1.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CCXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -0.75 Max: 105.2
Current: -1.5
0
105.2
» CCXI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CCXI Guru Trades in Q3 2015

Steven Cohen Sold Out
Chuck Royce 55,000 sh (-21.43%)
Jim Simons 24,700 sh (-80.61%)
» More
Q4 2015

CCXI Guru Trades in Q4 2015

Steven Cohen 19,400 sh (New)
Jim Simons 44,300 sh (+79.35%)
Chuck Royce 33,300 sh (-39.45%)
» More
Q1 2016

CCXI Guru Trades in Q1 2016

Jim Simons 169,054 sh (+281.61%)
Steven Cohen Sold Out
Chuck Royce 32,900 sh (-1.20%)
» More
Q2 2016

CCXI Guru Trades in Q2 2016

Chuck Royce Sold Out
Jim Simons 69,681 sh (-58.78%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:IMGN, OTCPK:NICXF, NAS:MNOV, OTCPK:ELVAF, OTCPK:CLVLF, NAS:ITEK, NAS:VTVT, NAS:CMRX, OTCPK:BNOEY, NAS:RXDX, NAS:CXRX, NAS:CNCE, NAS:SELB, NAS:CRBP, NAS:DMTX, NAS:ABUS, NAS:NVIV, AMEX:PFNX, NAS:SQNM, AMEX:AST » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 9.08
CCXI's Price/Owner Earnings (ttm) is ranked higher than
85% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. CCXI: 9.08 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CCXI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.78  Med: 7.49 Max: 9.45
Current: 9.08
6.78
9.45
P/B 4.54
CCXI's P/B is ranked lower than
54% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CCXI: 4.54 )
Ranked among companies with meaningful P/B only.
CCXI' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 2.74 Max: 4.98
Current: 4.54
0.74
4.98
P/S 92.45
CCXI's P/S is ranked lower than
83% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CCXI: 92.45 )
Ranked among companies with meaningful P/S only.
CCXI' s P/S Range Over the Past 10 Years
Min: 9.69  Med: 77.7 Max: 519.44
Current: 92.45
9.69
519.44
PFCF 7.02
CCXI's PFCF is ranked higher than
92% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. CCXI: 7.02 )
Ranked among companies with meaningful PFCF only.
CCXI' s PFCF Range Over the Past 10 Years
Min: 5.27  Med: 5.82 Max: 7.3
Current: 7.02
5.27
7.3
POCF 7.00
CCXI's POCF is ranked higher than
91% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. CCXI: 7.00 )
Ranked among companies with meaningful POCF only.
CCXI' s POCF Range Over the Past 10 Years
Min: 5.25  Med: 5.8 Max: 7.28
Current: 7
5.25
7.28
Current Ratio 5.53
CCXI's Current Ratio is ranked higher than
56% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CCXI: 5.53 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 5.53  Med: 10.74 Max: 19.54
Current: 5.53
5.53
19.54
Quick Ratio 5.53
CCXI's Quick Ratio is ranked higher than
58% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CCXI: 5.53 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 5.53  Med: 10.74 Max: 19.54
Current: 5.53
5.53
19.54
Days Sales Outstanding 22.85
CCXI's Days Sales Outstanding is ranked higher than
81% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CCXI: 22.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.84  Med: 77.86 Max: 260.05
Current: 22.85
5.84
260.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.70
CCXI's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CCXI: -6.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.5  Med: -10.85 Max: 0
Current: -6.7
-15.5
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.27
CCXI's Price/Net Cash is ranked higher than
53% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. CCXI: 6.27 )
Ranked among companies with meaningful Price/Net Cash only.
CCXI' s Price/Net Cash Range Over the Past 10 Years
Min: 1.95  Med: 4.16 Max: 7.68
Current: 6.27
1.95
7.68
Price/Net Current Asset Value 6.06
CCXI's Price/Net Current Asset Value is ranked higher than
53% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CCXI: 6.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CCXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.92  Med: 4.11 Max: 7.47
Current: 6.06
1.92
7.47
Price/Tangible Book 4.51
CCXI's Price/Tangible Book is ranked higher than
54% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. CCXI: 4.51 )
Ranked among companies with meaningful Price/Tangible Book only.
CCXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.56  Med: 3.29 Max: 4.94
Current: 4.51
1.56
4.94
Price/Median PS Value 1.19
CCXI's Price/Median PS Value is ranked lower than
56% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CCXI: 1.19 )
Ranked among companies with meaningful Price/Median PS Value only.
CCXI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.88 Max: 3.21
Current: 1.19
0.13
3.21
Earnings Yield (Greenblatt) (%) -34.13
CCXI's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CCXI: -34.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -257.62  Med: 0 Max: 0
Current: -34.13
-257.62
0

More Statistics

Revenue (TTM) (Mil) $2.80
EPS (TTM) $ -1.08
Beta1.36
Short Percentage of Float8.33%
52-Week Range $1.92 - 8.30
Shares Outstanding (Mil)47.76
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
Healthcare-Focused Michael Castor Added These Stocks to His Portfolio Last Quarter Sep 27 2016
ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with... Sep 01 2016
ChemoCentryx to Present at the Baird 2016 Global Healthcare Conference Aug 25 2016
CHEMOCENTRYX, INC. Financials Aug 17 2016
Edited Transcript of CCXI earnings conference call or presentation 8-Aug-16 9:00pm GMT Aug 09 2016
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Aug 09 2016
ChemoCentryx reports 2Q loss Aug 08 2016
ChemoCentryx reports 2Q loss Aug 08 2016
ChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 2016 Aug 08 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 08 2016
ChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
Q2 2016 ChemoCentryx Inc Earnings Release - After Market Close Aug 08 2016
ChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 2016 Aug 01 2016
ChemoCentryx to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference Jun 29 2016
ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
IBB Rose 0.9% before the Long Weekend May 31 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 27 2016
XBI and IHI Rose despite the Biotechnology Sector’s Sluggish Week May 16 2016
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... May 12 2016
Can The Uptrend Continue for ChemoCentryx (CCXI)? May 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)